AdvaMed® Advancements: Q1 2026 Report
Explore AdvaMed®’s Q1 2026 report on medtech policy, regulatory trends, reimbursement, and advocacy driving innovation and patient access.
Tariffs
Stay up to date on tariff policies that impact your global operations. This section provides insights on trade developments, regulatory changes, and AdvaMed’s advocacy to minimize tariff burdens on medtech manufacturers and maintain global supply chain stability.
IEEPA Tariff Refunds Are Coming: What Medtech Needs to Know
The U.S. Supreme Court recently marked a significant shift in the tariff landscape, learn what that means for your organization.
Navigating the ACCESS & TEMPO Models: A Direct Dialogue with CMMI & FDA Leaders
Watch AdvaMed’s® exclusive member-only webinar featuring a direct dialogue with CMS Innovation Center leadership on the newly released ACCESS & TEMPO Model. Attendees will gain critical insights into model performance…
ICYMI: AdvaMed’s Scott Whitaker on Supreme Court Tariffs Decision, Next Steps
Scott Whitaker, president and CEO ofAdvaMed®, the world’s largest trade association representing medtech innovators, released the following statement after Fridays’ Supreme Court ruling on tariffs. Today, he published a more fulsome readout on LinkedIn, available here.
The Supreme Court Struck Down IEEPA Tariffs – What Medtech Needs To Know
The U.S. Supreme Court recently marked a significant shift in the tariff landscape, learn what that means for your organization.
AdvaMed® Supports United States-Mexico-Canada Agreement Renewal
WASHINGTON—AdvaMed, the MedTech Association®, representing more than 650 medtech and health tech companies, the majority small businesses, today expressed support for renewal of the United States-Mexico-Canada Agreement (USMCA). Scott Whitaker,AdvaMed®…
AdvaMed® Plays Tariff Chess, Trump Plays Checkers
As tariff uncertainty continues in 2025,AdvaMed® plays tariff chess, advocating for predictable, zero-for-zero policies to protect medtech innovation and access.
AdvaMed® Advancements: Q4 2025 Report
AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.
AdvaMed® Calls U.S.-China Trade Announcement a “Positive Step” for U.S.-led Medtech
WASHINGTON—AdvaMed, the MedTech Association®, called the U.S.-China trade announcement a positive step toward supporting the U.S.-led medtech industry and its service to patients nationwide and globally.
AdvaMed® Advancements: Q3 2025 Report
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment,AdvaMed® remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to advancing…